NCT02179008View on ClinicalTrials.gov

Multi-center Phase II Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension

PHASE2CompletedINTERVENTIONAL
Enrollment

184

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions
Open-angle GlaucomaOcular Hypertension
Interventions
DRUG

DE-117 Low Dose ophthalmic solution

Low Dose DE-117 ophthalmic solution

DRUG

DE-117 Low/Middle Dose ophthalmic solution

Low/Middle Dose DE-117

DRUG

DE-117 Middle Dose ophthalmic solution

Middle Dose DE-117

DRUG

DE-117 Middle/High Dose ophthalmic solution

Middle/High Dose DE-117

DRUG

DE-117 High Dose ophthalmic solution

High Dose DE-117

DRUG

latanoprost ophthalmic solution 0.005%

0.005% latanoprost

Trial Locations (14)

14618

Rochester

27262

High Point

30076

Roswell

30260

Morrow

33773

Largo

44115

Cleveland

77005

Houston

78240

San Antonio

78731

Austin

85225

Chandler

90701

Artesia

90806

Long Beach

91204

Glendale

92663

Newport Beach

All Listed Sponsors
lead

Santen Inc.

INDUSTRY

NCT02179008 - Multi-center Phase II Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension | Biotech Hunter | Biotech Hunter